Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.

Abstract : For this patient population, low dose metronomic cyclophosphamide prednisolone might be a viable alternative. Its convenient oral administration, low cost, and lack of toxicity justify further studies alone, or in combination with other agents in HRPC patients.
Type de document :
Article dans une revue
Anticancer Research, International Institute of Anticancer Research, 2010, 30 (10), pp.4317-23
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00555027
Contributeur : Grégoire Mignot <>
Soumis le : mercredi 12 janvier 2011 - 09:17:19
Dernière modification le : dimanche 11 février 2018 - 01:14:43

Identifiants

  • HAL Id : inserm-00555027, version 1
  • PUBMED : 21036758

Collections

Citation

Sylvain Ladoire, Jean-Christophe Eymard, Sylvie Zanetta, Grégoire Mignot, Etienne Martin, et al.. Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.. Anticancer Research, International Institute of Anticancer Research, 2010, 30 (10), pp.4317-23. 〈inserm-00555027〉

Partager

Métriques

Consultations de la notice

143